| 000 | 01756nam a22003497a 4500 | ||
|---|---|---|---|
| 008 | 221018s20222022 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a0889-8588 | ||
| 024 | _a10.1016/j.hoc.2022.07.006 [doi] | ||
| 024 | _aS0889-8588(22)00074-0 [pii] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a36154782 | ||
| 245 | _aCytotoxic Chemotherapy in Advanced Pancreatic Cancer. [Review] | ||
| 251 | _aHematology - Oncology Clinics of North America. 2022 Sep 22 | ||
| 252 | _aHematol Oncol Clin North Am. 2022 Sep 22 | ||
| 253 | _aHematology/oncology clinics of North America | ||
| 260 | _c2022 | ||
| 260 | _fFY2023 | ||
| 260 | _p2022 Sep 22 | ||
| 265 | _saheadofprint | ||
| 266 | _d2022-10-20 | ||
| 520 | _aAdvanced pancreatic cancer remains one of the deadliest malignancies in 2022. Although there has been significant progress in treatment options with improved outcomes in many cancers, this growth has been slow in pancreatic cancer. This article examines specific components of approved first- and second-line therapies for advanced pancreatic cancer treatment and their effectiveness and concludes with a brief exploration of future directions for targeted therapies. Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 546 | _aEnglish | ||
| 650 | _aIN PROCESS -- NOT YET INDEXED | ||
| 656 | _aHematology & Oncology Fellowship | ||
| 656 | _aMedStar Georgetown University Hospital/MedStar Washington Hospital Center | ||
| 657 | _aJournal Article | ||
| 657 | _aReview | ||
| 700 |
_aRehman, Muneeb _bMGUH _cHematology & Oncology Fellowship _dMD _eFellow PGY 6 |
||
| 790 | _aKhaled A, Noel M, Rehman M | ||
| 856 |
_uhttps://dx.doi.org/10.1016/j.hoc.2022.07.006 _zhttps://dx.doi.org/10.1016/j.hoc.2022.07.006 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c280 _d280 |
||